

DAFTAR PUSTAKA

- Anisimov, V.N., 2003. The relationship between aging and carcinogenesis : a critical appraisal. *Oncol hematol*, 45, pp.277–304.
- Balkwill, F., 2004. The significance of cancer cell expression of the chemokine receptor CXCR4. *Semin in Cancer Biol*, 14, pp.171–179.
- Brown, J. & Frumovitz, M., 2014. Mucinous Tumors of the Ovary : Current Thoughts on Diagnosis and Management. *Curr Oncol Rep*, 16:389, pp.1–9.
- Chatterjee, S., Azad, B., and Nimmagadda, S., 2015. The intricate role of CXCR4 in cancer. *Adv Cancer Res*, 124, pp.31–82.
- Cho, K.R. & Shih, I., 2009. Ovarian Cancer. *Annu Rev Pathol Mech Dis*, pp.287–313.
- Deng, F. et al., 2017. Age is associated with prognosis in serous ovarian carcinoma. *J Ovarian Res*, 10:36, pp.1–9.
- Ezzati, M. et al., 2014. Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. *Int Sch Res Notices*, pp.1–10.
- Ferlay, J. et al., 2012. Cancer incidence and mortality worldwide : sources , methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, pp.1–76.
- Figueras, A. et al., 2017. A role for cxcr4 in peritoneal and hematogenous ovarian cancer dissemination. *Clin Cancer Res*, pp.1–36.
- Gil, M. et al., 2015. CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells. *J Immunol*, 193(10), pp.5327–5337.
- Grimley, P.M., Matsuno, R.K., Rosenberg, P.S., Henson, D.E., Schwartz, A.M., and Anderson, W.F., 2009. Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas. *Cancer Epidemiol Biomarkers Prev*, 18, pp.2256–2261.
- Guo, L., Cui, Z., Zhang, J., and Huang, Y., 2011. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma. *Chin J Cancer*, 30(5), pp.336–343.
- Guo, Q. et al, 2017. CXCL12-CXCR4 axis promotes proliferation, migration, invasion, and metastasis of ovarian cancer. *Oncol Res*, 22, pp.247–258.

- Horvath, L.E., Werner, T., Boucher K., and Jones, K., 2013. The relationship between tumor size and stage in early versus advanced ovarian cancer. *Med Hypotheses*, 80(5), pp.684–687.
- Kishima, M.O. et al., 2015. Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance. *Anal Cell Pathol*, pp.1–6.
- Koshiyama, M., Matsumura, N. & Konishi, I., 2014. Recent concepts of ovarian carcinogenesis: Type I and Type II. *Biomed Res Int*, pp.1–11.
- Kriplani, D. and Patel, M.M., 2013. Immunohistochemistry : A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary. *South Asian J Cancer*, 2(4), pp.254–258.
- Kurman, R.J., Ellenson, L.H. & Ronnett, B.M., 2011. *Blaustein's Pathology of the Female Genital Tract: Surface epithelial tumor of ovary*, pp. 679-785.
- Li, J., Fadare, O., Xiang, L., Kong, B., and Zheng, W., 2012. Ovarian serous carcinoma : recent concepts on its origin and carcinogenesis. *J Hematol Oncol*, 5(8), pp.1–11.
- Lim, D. and Oliva, E., 2013. Precursors and pathogenesis of ovarian carcinoma. *Pathology*, 45(April), pp.229–242.
- Liu, C. et al., 2014. The Prognostic Value of CXCR4 in Ovarian Cancer : A Meta-Analysis. *PLoS One*, 9(3), pp.1–7.
- Lu, C.L., Ji, Y., Ge, D., Guo, J., and Ding, J.Y., 2011. The expression of CXCR4 and its relationship with matrix metalloproteinase- 9 / vascular endothelial growth factor in esophageal squamous cell cancer. *Dis Esophagus*, 24, pp.283–290.
- Mao, T.L., Fan, K.F. & Liu, C.L., 2017. Targeting the CXCR4/CXCL12 Axis in Treating Epithelial Ovarian Cancer. *Gene Ther*, pp.1–34.
- McCluggage, W.G., 2011. Morphological subtypes of ovarian carcinoma : a review with emphasis on new developments and pathogenesis. *Pathology*, 43, pp.420–432.
- Meurs, H.S. Van et al., 2013. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. *Eur J Cancer*, 49(15), pp.3191–3201.

- Nolan, T., Hands, R.E. & Bustin, S.A., 2006. Quantification of mRNA using real-time RT-PCR. *Nat Protoc*, 1(3), pp.1559–1582.
- Nucci, M., Crum, C. & Lee, K., 2011. *Diagnostic Gynecologic and Obstetric Pathology: The Pathology of Pelvic-Ovarian Epithelial Tumors*, pp. 818-862.
- Okugawa, K., Hirakawa, T., Fukushima, K., Kamura, T., Amada, S., and Nakano, H., 2001. Relationship between age, histological type, and size of ovarian tumors. *Int J Gynecol Obstet*, 74, pp.45–50.
- Onal, Y. et al., 2017. Assessment of Prognostic Factors in Epithelial Ovarian Cancer. *Ejmo*, 1(2), pp.61–68.
- Prat, J., 2012. New insights into ovarian cancer pathology. *Ann Oncol*, 23(10), pp.1–7.
- Quattrocchi, L., Sisson, M., Green, M., Martin, S.G., Durrant, L., and Deen, S., 2013. Expression of angiogenic chemokines in ovarian clear cell carcinoma. *J Obstet Gynaecol Res*, 39(1), pp.297–304.
- Rainczuk, A., Rao, J., Gathercole, J., and Stephens, A.N., 2012. The emerging role of CXC chemokines in epithelial ovarian cancer. *Reproduction*, 144, pp.303–217.
- Razi, S., Ghoncheh, M., Hafshejani, A.M., Aziznejhad, H., Mohammadian, M., and Salehiniya, H., 2016. The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia. *Ecancer*, 10:628, pp.1–11.
- Reid, B.M., Permeth, J.B. & Sellers, T.A., 2017. Epidemiology of ovarian cancer : a review. *Cancer Biol Med*, 10:628, pp.9–32.
- Sabatier, R. et al., 2015. Prognostic Factors for Ovarian Epithelial Cancer in the Elderly A Case-Control Study. *Int J Gynecol Cancer*, 25(5), pp.815–822.
- Saha, M., Banerjee, A. & Datta, A., 2018. Histological patterns of Ovarian neoplasms – A five year experience in North-East India. *Int J Med and Dent Sci*, 7, pp.1576–1581.
- Salomonsson, E. Ghoncheh, M., Hafshejani, A.M., Aziznejhad, H., Mohammadian, M., and Salehiniya, H., 2013. Imaging CXCL12-CXCR4 Signaling in Ovarian Cancer Therapy. *PLoS One*, 8(1), pp.1–10.
- Seidman, J. et al., 2014. *Tumours of the Ovary; WHO Classification of Tumours of Female Reproductive Organs*, pp.11–41.

- Shen, X., Wang, S., Wang, H., Liang, M., Xiao, L., and Wang, Z., 2009. The Role of SDF-1 / CXCR4 Axis in Ovarian Cancer Metastasis. *J Huazhong Univ Sci Technol*, 29(3), pp.363–367.
- Shih, I. & Kurman, R.J., 2004. Ovarian Tumorigenesis. *Am J Pathol*, 164(5), pp.1511–1518.
- Tang, L., Zheng, M., Xiong, Y., Ding, H., and Liu, F., 2008. Clinical characteristics and prognosis of epithelial ovarian cancer in young women. *Chin J Cancer*, 27(9), pp.238–241.
- Teicher, B.A. & Fricker, S.P., 2010. CXCL12 (SDF-1)/CXCR4 pathway in cancer. *Clin Cancer Res*, (11), pp.2927–2932.
- Tian, Q., Lu, B., Ye, J., Lu, W., Xie, X., and Wang, X., 2016. Early stage primary ovarian mucinous carcinoma : Outcome-based clinicopathological study in comparison with serous carcinoma. *J Int Med Res*, 44(2), pp.357–366.
- Vang, R., Shih, L.-M. & Kurman, R., 2009. Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems. *Adv Anat Pathol*, 16(5), pp.267–282.
- Vereczkey, I. et al., 2011. Molecular characterization of 103 ovarian serous and mucinous tumors. *Pathol Oncol Res*, 17, pp.551–559.
- Wang, D., Lou, N., Zeng, C., Zhang, F., and Chen, F., 2009. Expression of CXCL12 / CXCR4 and its correlation to prognosis in esophageal squamous cell carcinoma. *Chin J Cancer*, 28(2), pp.154–158.
- Wang, J. et al., 2011. Silencing of CXCR4 Blocks Progression of Ovarian Cancer and Depresses Canonical Wnt Signaling Pathway. *Int J Gynecol Cancer*, 21(6), pp.981–987.
- Wang, Y., Xie, Y. & Oupicky, D., 2017. Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery. *Curr Pharmacol Rep*, 2(1), pp.1–10.
- White, M.C., Holman, D.M., Boehm, J.E., Peipins, L.A, Grossman, M., and Henley, S.J., 2015. Age and cancer risk. *Am J Prev Med*, 46, pp.1–16.
- Yasuoka, H. et al., 2008. Cytoplasmic CXCR4 expression in breast cancer : induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. *BMC Cancer*, 10, pp.1–10.
- Zhang, N. et al., 2012. Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients. *Exp Ther Med*, 3, pp.973–982.

Zhao, H., Guo, L., Zhao, H., Zhao, J., Weng, H., and Zhao, B., 2014. CXCR4 over-expression and survival in cancer : A system review and meta-analysis. *Oncotarget*, 6(7), pp.5022–5040.